Valeant CDS quake with fear of ‘phantoms’
Wednesday’s shock market development saw short-selling research firm Citron allege that biotech firm Valeant Pharmaceutical inflated its sales figures by selling to “phantom captive pharmacies” in a plot reminiscent of the Enron scandal of over a decade ago.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts
